It is also worth mentioning that KRAS mutations have been recently linked with an increased propensity of melanoma tumors to metastasize to the brain and, therefore, envisioned as valuable biomarkers of patient risk stratification in clinical settings [40]. This evidence concerns the gene KRAS and melanoma.